These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35731974)

  • 21. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
    de Vries NL; van de Haar J; Veninga V; Chalabi M; Ijsselsteijn ME; van der Ploeg M; van den Bulk J; Ruano D; van den Berg JG; Haanen JB; Zeverijn LJ; Geurts BS; de Wit GF; Battaglia TW; Gelderblom H; Verheul HMW; Schumacher TN; Wessels LFA; Koning F; de Miranda NFCC; Voest EE
    Nature; 2023 Jan; 613(7945):743-750. PubMed ID: 36631610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TCF1
    Koh J; Kim S; Woo YD; Song SG; Yim J; Han B; Lim S; Ahn HK; Mun S; Kim JS; Keam B; Kim YA; Lee SH; Jeon YK; Chung DH
    Eur J Cancer; 2022 Oct; 174():10-20. PubMed ID: 35970031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.
    Ou L; Liu S; Wang H; Guo Y; Guan L; Shen L; Luo R; Elder DE; Huang AC; Karakousis G; Miura J; Mitchell T; Schuchter L; Amaravadi R; Flowers A; Mou H; Yi F; Guo W; Ko J; Chen Q; Tian B; Herlyn M; Xu X
    EBioMedicine; 2023 Jun; 92():104614. PubMed ID: 37229906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cytotoxic molecule granulysin is capable of inducing either chemotaxis or fugetaxis in dendritic cells depending on maturation: a role for Vδ2
    Sparrow EL; Fowler DW; Fenn J; Caron J; Copier J; Dalgleish AG; Bodman-Smith MD
    Immunology; 2020 Nov; 161(3):245-258. PubMed ID: 32794189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.
    Ferrarini M; Heltai S; Pupa SM; Mernard S; Zocchi R
    J Natl Cancer Inst; 1996 Apr; 88(7):436-41. PubMed ID: 8618235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 30. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma.
    Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y
    J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
    Varesano S; Zocchi MR; Poggi A
    Front Immunol; 2018; 9():998. PubMed ID: 29867975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
    Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
    J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.
    Zou Y; Yaguchi T
    Exp Dermatol; 2023 Mar; 32(3):264-275. PubMed ID: 36645031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2
    He W; Hu Y; Chen D; Li Y; Ye D; Zhao Q; Lin L; Shi X; Lu L; Yin Z; He X; Gao Y; Wu Y
    Clin Transl Med; 2022 Apr; 12(4):e800. PubMed ID: 35390227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
    Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
    Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
    Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
    J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral administration of garlic-derived nanoparticles improves cancer immunotherapy by inducing intestinal IFNγ-producing γδ T cells.
    Xu J; Yu Y; Zhang Y; Dai H; Yang Q; Wang B; Ma Q; Chen Y; Xu F; Shi X; Liu Z; Wang C
    Nat Nanotechnol; 2024 Oct; 19(10):1569-1578. PubMed ID: 39054386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model.
    Hu X; Que W; Hirano H; Wang Z; Nozawa N; Ishii T; Ishizuka M; Ito H; Takahashi K; Nakajima M; Tanaka T; Zhu P; Guo WZ; Li XK
    Cancer Sci; 2021 Jul; 112(7):2652-2663. PubMed ID: 33934440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer.
    Nada MH; Wang H; Hussein AJ; Tanaka Y; Morita CT
    Oncoimmunology; 2021; 10(1):1989789. PubMed ID: 34712512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.